#37 - Multidisciplinary Association for Psychedelic Studies (MAPS)

 This week’s episode features Richard ‘Rick’ Doblin, who is the founder and director of the Multidisciplinary Association for Psychedelic Studies (MAPS) – a non-profit research organisation he established in 1986. Somewhere between getting an undergraduate degree in psychology and a doctorate in public policy, Rick, having had discovered psychedelics, began his fight against unjustified  …


MDMA for Alcohol Use Disorder

In this webinar, Dr Ben Sessa explains how MDMA therapy could treat alcohol use disorder (alcoholism), based on results from his recent safety and tolerability study. He gives background into the psychological trauma which often causes addiction and alcohol use disorder, and how modern psychiatry struggles to treat these conditions at the root cause. He  …


Women in Psychedelic Science - Part 3

The Contradictions of Ketamine: results from a new clinical trial treating alcohol use disorder – Prof Celia Morgan Celia Morgan is a Professor of Psychopharmacology and Head of Psychology at the University of Exeter. She started researching ketamine at UCL for her PhD with Val Curran over twenty years ago and branched out into research  …


#23 - Neuropsychopharmacology

The tables have been turned in this one-off special of the Drug Science podcast. In this episode, Professor David Nutt is interviewed by renowned singer-songwriter – Joss Stone. Professor Nutt is the Chair of the Drug Science Scientific Committee and currently the Edmund J Safra Professor of Neuropsychopharmacology and Head of the Neuropsychopharmacology Unit at  …


#22 - Medical Psychedelics Working Group

On July 14th 2020, the UK’s leading independent scientific body on drugs has launched the Drug Science Medical Psychedelics Working Group. Building off the success of the Medical Cannabis Working Group, the Medical Psychedelics Working Group is a consortium of Drug Science experts, leading academics, researchers and policy specialists, supported by industry partners. The group’s aim  …


Medical MDMA Student Educational Slides

MDMA (3,4-Methyl​enedioxy​methamphetamine) was first synthesised in 1912 by chemists at the pharmaceutical company, Merck in Germany. In 1985, MDMA was placed in schedule 1, resulting in no research being conducted into the potential therapeutic applications of MDMA between 1985 – 2000. However, since then, MDMA has been included in over 5000 academic articles and administered to  …


Launch of the Medical Psychedelics Working Group

On Tuesday July 14th, 2020, Drug Science will launch a new working group of experts, policy makers and scientists. Its primary role is to campaign for the rescheduling of all psychedelic drugs for research and medical purposes. However, current UK regulations have created serious and considerable barriers to legitimate research associated with Schedule 1 regulations.  …